ASCO 2018 | Trial updates in NHL: RELEVANCE, polatuzumab, TRANSCEND-NHL-001 & Hu5F9-G4
Cutting-edge trial data in the field of lymphoma was presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Here, Nathan Fowler, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the key data on show. Prof. Fowler, who presented data from the RELEVANCE trial (NCT01476787), highlights the promising results from the combination of bendamustine-rituximab plus the antibody-drug conjugate polatuzumab vedotin (NCT02257567) for relapsed/refractory follicular and diffuse large B-cell lymphoma. In addition, he picks out the TRANSCEND-NHL-001 trial (NCT02631044) of CAR T-cell product lisocabtagene maraleucel, and a trial of a promising novel anti-CD47 antibody, Hu5F9-G4 (NCT02953509), both for relapsed/refractory non-Hodgkin lymphoma.
Get great new content delivered to your inboxSign up